- Alantos Pharmaceuticals Initiates Phase 1 Clinical Studies With Lead Compound For Type II Diabetes
Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and Osteoarthritis/inflammation, today announced that it has initiated a Phase 1 clinical study with its first clinical candidate, ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), for the treatment of type II diabetes. - Tips For Handling Summer Heat For People With Diabetes
The heat being experienced in many parts of the nation these days is tough enough for the average healthy person, but for the estimated 21 million Americans with diabetes, special precautions may be required, according to experts at Joslin Diabetes Center in Boston. - Diabetes Educators Applaud 7,500 Professional Websites Launched By DLife
dLife, the award-winning diabetes consumer resource, today announced from the Annual Meeting of The American Association of Diabetes Educators taking place in Los Angeles, the launch of an innovative tool that will bring diabetes educators into the age of 24/7 interactive patient management. - Spherix Signs Anaclim To Support Diabetes Clinical Trial
Spherix Incorporated (Nasdaq: SPEX) has signed an agreement with Anaclim, LLC to conduct the U.S. portion of its Phase 3 clinical trial on the use of Naturlose(R) as a treatment for Type 2 diabetes. The trial is being split into portions conducted in Australia and in the United States to cover all required demographic groups. Anaclim is the only dedicated, full service, minority- focused contract research organization in the U.S. - New Study Adds To Body Of Evidence Supporting That Diachrome(R) Can Significantly
Nutrition 21 today commented on a study published in the August issue of Diabetes Care(1) showing that daily supplementation with chromium picolinate -- an active ingredient in Diachrome(R) -- can improve insulin sensitivity and glucose control in people with type 2 diabetes when taken in conjunction with an oral antidiabetic agent better than an oral antidiabetic agent alone. - Insulin Pathway Component Explains Insulin Resistance, Age-associated Metabolic Syndrome
Metabolic syndrome, an aging-associated group of disorders that includes insulin resistance, heart disease and high lipid levels, may be treatable thanks to a newly discovered role for a regulatory gene, according to a team of scientists at the Burnham Institute for Medical Research. - Low-fat Vegan Diet Rivals Oral Diabetes Medications In Federally Funded Study
A low-fat vegan diet treats type 2 diabetes more effectively than a standard diabetes diet and may be more effective than single-agent therapy with oral diabetes drugs, according to a study in the August issue of Diabetes Care, a journal published by the American Diabetes Association. Study participants on the low-fat vegan diet showed dramatic improvement in four disease markers: blood sugar control, cholesterol reduction, weight control, and kidney function. - Juvenile Diabetes Research Foundation Names The City Of Hope A JDRF Islet Cell Transplant Center
The Juvenile Diabetes Research Foundation (JDRF), the world's largest charitable funder of type 1 diabetes research, announced today that it has named The City of Hope National Medical Center in Los Angeles as a JDRF Islet Cell Transplant Center. - Living With Diabetes
Everyone living with diabetes has experienced the curious questions from well-meaning, but uninformed, onlookers who might be taken aback by a hypodermic needle, a pump, or a blood glucose kit. "Diabetic Encounters of the First Kind," an article in the August 2006 issue of Diabetes Health Magazine, takes a humorous look at these interesting encounters. - First Inhaled Form Of Insulin Launched, UK
Pfizer Ltd has announced the launch of Exubera® (inhaled insulin), the first alternative to injections to become available in the UK. - End To Insulin Injections For People With Rare Form Of Diabetes
Up to half of people diagnosed with diabetes in the first six months of life can now replace their insulin injections with tablets.
Research, initially funded by Diabetes UK, recently identified that changes in a gene (Kir6.2) cause a rare form of diabetes that occurs in infancy. - Diabetes Type 1 Rates Very High In UK
Research has shown that the UK has one of the highest rates of Type 1 diabetes in the world.
Information collated from 57 countries between 1990 and 1999 found the average annual increase for the UK to be 4 per cent. This compares to 2.8 per cent worldwide and 3.2 per cent for Europe. - Asthma UK Issues Advice On Long Acting Beta-Agonists
Asthma UK has issued advice for healthcare professionals in response to media coverage generated by an editorial published in the Journal of the Royal Society of Medicine on a 2003 US clinical trial into long-acting reliever inhalers. - MicroIslet Transplantation Studies In Diabetic Primates Successful At Six-Month Milestone
MicroIslet, Inc. (Amex: MII), a biotechnology company engaged in the research, development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, today announced that primate subjects in ongoing studies have continued to exhibit improved glycemic control over a six-month period by means of MicroIslet's proprietary microencapsulated porcine islet transplantation treatment approach. - 'My Pocket Doctor", A New Braille Diabetes Reference Guide Now Available From Pocket Reference
Pocket Reference Journals, a medical publisher of health journals has just published it's first journal in braille for the newly diagnosed blind diabetic. It's written by an endocrinologist, certified diabetes educator, and a registered dietitian. - Exercise Boost For Diabetes Patients Battling The Bulge
A pilot exercise referral scheme developed by Guy's and St Thomas' NHS Foundation Trust and evaluated by London South Bank University (LSBU) could help diabetes sufferers lose weight and manage their condition better. - American Diabetes Association And Joint Commission Collaborate On JointCommission Inpatient Diabetes
Two of the nation's leaders in improving health care for Americans are collaborating to recognize hospital inpatient diabetes programs that meet national quality standards and raise the quality of care provided to patients with diabetes. - Novo Nordisk Sues Pfizer For Patent Infringement Related To Exubera®
Novo Nordisk announced today that the company has filed a lawsuit against Pfizer claiming that Pfizer's product Exubera® infringes patents owned by Novo Nordisk. The patents cover inhaled insulin treatment for diabetes. - Marketing Authorisation Granted For Competact™ (pioglitazone/metformin) For Type 2 Diabetes InEurope
Takeda Pharmaceutical Company Limited ("Takeda") today announced that on July 31, 2006, Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe") was granted a marketing authori- sation for Competact™, a fixed combination tablet of ACTOS® (pioglitazone HCl) 15mg and metformin HCl 850mg from the European Commission. - Investigational New Class Of Oral Medication For Type 2 Diabetes Patients, Sitagliptin
Phase III clinical trials for an investigational new class of oral medication for patients with type 2 diabetes, sitagliptin (Development Code: MK-0431/ONO-5435), have begun in Japan. Sitagliptin, developed by Merck (Merck & Co., Inc., Whitehouse Station, New Jersey, USA) is a member of a potentially new class of oral drugs (dipeptidyl peptidase-4 [DPP-4] inhibitors) that enhances the body's own ability to lower blood sugar (glucose) when it is elevated. - Compound In Dairy Products Targets Diabetes
Fatty acids commonly found in dairy products have successfully treated diabetes in mice, according to a researcher at Penn State. The compounds, known as conjugated linoleic acids (CLA), have also shown promising results in human trials, signaling a new way of potentially treating the disease without synthetic drugs. - A Designer Approach To Regulating Autoimmunity In Diabetes
Type 1 diabetes is an autoimmune disorder in which the body's own immune system attacks the beta cells of the pancreas, destroying or damaging them sufficiently to reduce or impair insulin production. Therefore, shutting down the autoreactive T cells that attack beta islet cells is one therapeutic approach that researchers have been investigating. - Traditional Chinese Medicine For Diabetes Has Scientific Backing
Reports of a traditional Chinese medicine having beneficial effects for people suffering from type 2 diabetes now has some scientific evidence to back up the claims. A collaboration between Chinese, Korean, and Australian scientists at Sydney's Garvan Institute, has revealed that the natural plant product berberine could be a valuable new treatment. - New Report Suggests Ways Electronic Disease Registries Can Improve Diabetes Care
Electronic patient registries can help health care professionals improve care of diabetes patients, according to a report published today by the Hudson Center for Health Equity & Quality (Hcheq). However, the report notes physicians will have difficulty installing such systems without financial assistance and ongoing technical support. The report is based on a roundtable discussion of the nation's leading diabetes registry pioneers held by Hcheq on Nov. 16, 2005. - FDA Approves Duetact(TM) (pioglitazone HCl And Glimepiride) For The Treatment Of Type 2 Diabetes
Takeda Pharmaceuticals North America, Inc. (TPNA) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for duetact(TM) (pioglitazone HCl and glimepiride), pronounced "Duet Act," for the treatment of type 2 diabetes. - Early-onset Of Diabetes Associated With Increased Risk Of Kidney Disease And Death Before Age 55
Onset of type 2 diabetes before age 20 in a population of American Indians is associated with a substantially increased risk of end-stage kidney disease and death between 25 and 55 years of age, according to a study in the July 26 issue of JAMA. - NicOx To Move NCX 4016 Forward In Phase 2 For Diabetes
NicOx S.A. (Eurolist: NICOX) today announced its decision to move NCX 4016 forward in clinical development as a novel insulin sensitizing agent for the treatment of type 2 diabetes. The Company expects to initiate two phase 2 studies within the next 6 months. These trials will have the goal of confirming the mechanism of action of NCX 4016 as an insulin sensitizer and demonstrating a clinical benefit in the treatment of type 2 diabetes. - Pulsed Infrared Light Therapy System Used In Published Study On Diabetic Peripheral Neuropathy
Another type of Infrared Therapy technology can now add itself to the list of having published studies on treating diabetic peripheral neuropathy (DPN) with monochromatic or dual wave Infrared Therapy, also known as pulsed infrared light therapy. Although the Healthlight(TM) brand name was not used in this study, The Healthlight(TM) system (http://www.infraredtherapy.com) is nearly identical in specifications as the brand utilized in the study. - Gene Variant Increases Risk Of Type 2 Diabetes
Researchers have confirmed that a gene variant confers susceptibility to type 2 diabetes in participants of the Diabetes Prevention Program (DPP), a large clinical trial in adults at increased risk for developing type 2 diabetes. The finding, published in the July 20, 2006, issue of the New England Journal of Medicine, follows the discovery by deCode Genetics that a variant in a gene called TCF7L2 predisposes people to type 2 diabetes. - Abbott Reminds U.S. FreeStyle(R) And FreeStyle Flash(R) Blood Glucose Meter Users To Verify Units
Abbott (NYSE: ABT) is reminding users of its FreeStyle(R) and FreeStyle Flash(R) blood glucose meters in the United States to check to make sure their meter is displaying the correct unit of measure (milligrams per deciliter, mg/dL) and strip calibration code each time they test.
|
